BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates